Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.06M | 27.87M | 25.49M | 25.23M | 27.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.06M | 27.87M | 25.49M | 25.23M | 27.17M |
| Cost of Revenue | 894.00K | 1.18M | 958.00K | 770.00K | 979.00K |
| Gross Profit | 21.16M | 26.70M | 24.53M | 24.46M | 26.19M |
| SG&A Expenses | 15.80M | 22.32M | 17.52M | 17.84M | 15.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.79M | 27.21M | 21.26M | 21.96M | 19.10M |
| Operating Income | 2.27M | 663.00K | 4.23M | 3.26M | 8.07M |
| Income Before Tax | 4.64M | 772.00K | 3.93M | 6.04M | 12.48M |
| Income Tax Expenses | 901.00K | 203.00K | 1.07M | 1.50M | 2.55M |
| Earnings from Continuing Operations | 3.73M | 569.00K | 2.86M | 4.54M | 9.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.04M | -668.00K | -1.73M | -1.01M | -2.40M |
| Net Income | 2.70M | -99.00K | 1.12M | 3.53M | 7.53M |
| EBIT | 2.27M | 663.00K | 4.23M | 3.26M | 8.07M |
| EBITDA | 2.81M | 1.13M | 4.69M | 3.50M | 8.49M |
| EPS Basic | 0.03 | 0.00 | 0.01 | 0.04 | 0.09 |
| Normalized Basic EPS | 0.02 | 0.00 | 0.01 | 0.03 | 0.06 |
| EPS Diluted | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Normalized Diluted EPS | 0.02 | 0.00 | 0.01 | 0.03 | 0.05 |
| Average Basic Shares Outstanding | 86.42M | 85.95M | 85.64M | 85.50M | 83.27M |
| Average Diluted Shares Outstanding | 101.97M | 85.95M | 102.64M | 104.33M | 102.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |